Subject: ACC
Cannabics Pharmaceuticals Announces That Seedo is to End Pre-Sales and Commence Delivery of Its Automated Growing Devices
Aug. 22, 2018, TEL AVIV, Israel and BETHESDA, Maryland /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that Eroll Grow Tech Ltd ("Seedo"), developer of the world's first fully-automated grow device designed specifically for medical cannabis, is to end Seedo's pre-sale on September 12th at midnight EST, and commence scheduled delivery of its first units to customers in the coming weeks.
Recently CNBX partnered with Seedo to help bring forth the company's immediate vision of supplying personalized growing units into the market, and to cooperate on enabling consistent, pesticide free, pharmaceutical-grade cannabis worldwide on a commercial scale.
Eyal Barad, CEO of Cannabics Pharmaceuticals, said, "We are eager to begin empowering patients to take control over their personal medical cannabis supply, and to begin engaging into a two-way interaction with patients to share their inputs - which along with our lab's scientific data will allow us to provide current and future patients with relevant information in order to make wiser decisions concerning cannabinoid-based treatments."
"The commencement of device delivery marks the culmination of our combined efforts to bring together interdisciplinary knowledge to present patients with the means to ensure a safe, reliable supply of medical cannabis," said Seedo CEO, Zohar Levy. "By offering remote control over the automated growing process, we are ensuring optimal growth outcomes through our proprietary AI algorithm. We have gone to great lengths to combine multidisciplinary talent to create the world's first and only self-growing machine, which ultimately will also be used at an industrial scale."
About Cannabics Pharmaceuticals
Cannabics Pharmaceuticals Inc. (CNBX) is a United States-based public company that is developing a platform that leverages big data and artificial intelligence to develop cannabinoid-based therapies for palliative care and cancer treatments that are more precise to a patient's profile and specific cancer. Cannabics' approach can also be used to help develop cannabinoid-based therapies as a preventive or primary cancer treatment ? not just palliative, the way it's being used now. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move medical cannabinoids into the future of cancer therapies.
The company's R&D is based in Israel, where it is licensed by the Health Ministry to conduct scientific and clinical research on cannabinoid formulations. For more information, please visit www.cannabics.com.
About Seedo
Seedo is an Israeli company with Subsidiaries in the US and Europe, that developed the world's first fully-automated device managed and controlled by an artificial intelligent algorithm and monitored by smart phone App. Seedo lets consumers grow their own herbs and vegetables in the comfort of their own home, effortlessly. Seedo controls and monitors the growing process, from seed to plant, while providing optimal lab conditions to assure premium quality produce year-round. Company goal is to simplify the growing process, making it accessible for everyone, without compromising on quality. Visit Seedo at: www.seedolab.com.
Disclaimer:
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, Cannabics Pharmaceuticals' latest 10-Q Report filed on July 16th, 2018. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc. which are condoned by the Company must emanate from the Company itself, and bear our name as its Source.
Media Contact
Liz Crumpacker
[email protected]
+1-(646)-866-9215
SOURCE Cannabics Pharmaceuticals Inc.
These press releases may also interest you
|
News published on and distributed by:
